These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 24382688

  • 1. CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.
    Chen YP, Lin HJ, Chen JS, Tsai MY, Hsieh HP, Chang JY, Chen NF, Chang KC, Huang WT, Su WC, Yang ST, Chang WC, Hung LY, Chen TY.
    Int J Cancer; 2014 Aug 01; 135(3):751-62. PubMed ID: 24382688
    [Abstract] [Full Text] [Related]

  • 2. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
    Gessner A, Thomas M, Castro PG, Büchler L, Scholz A, Brümmendorf TH, Soria NM, Vormoor J, Greil J, Heidenreich O.
    Leukemia; 2010 Oct 01; 24(10):1751-9. PubMed ID: 20686504
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
    Nishioka C, Ikezoe T, Yang J, Udaka K, Yokoyama A.
    Leuk Res; 2011 Jul 01; 35(7):932-9. PubMed ID: 21550660
    [Abstract] [Full Text] [Related]

  • 5. HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia.
    Whelan JT, Ludwig DL, Bertrand FE.
    Leukemia; 2008 Jun 01; 22(6):1161-9. PubMed ID: 18337761
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combined effects of the two reciprocal t(4;11) fusion proteins MLL.AF4 and AF4.MLL confer resistance to apoptosis, cell cycling capacity and growth transformation.
    Gaussmann A, Wenger T, Eberle I, Bursen A, Bracharz S, Herr I, Dingermann T, Marschalek R.
    Oncogene; 2007 May 17; 26(23):3352-63. PubMed ID: 17130830
    [Abstract] [Full Text] [Related]

  • 9. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
    Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS.
    Breast Cancer Res Treat; 2013 Oct 17; 141(3):397-408. PubMed ID: 24091768
    [Abstract] [Full Text] [Related]

  • 10. AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice.
    Tamai H, Miyake K, Yamaguchi H, Takatori M, Dan K, Inokuchi K, Shimada T.
    Blood; 2012 Jan 05; 119(1):64-71. PubMed ID: 22025528
    [Abstract] [Full Text] [Related]

  • 11. t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL.
    Kumar AR, Yao Q, Li Q, Sam TA, Kersey JH.
    Leuk Res; 2011 Mar 05; 35(3):305-9. PubMed ID: 20869771
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras.
    Chu SH, Song EJ, Chabon JR, Minehart J, Matovina CN, Makofske JL, Frank ES, Ross K, Koche RP, Feng Z, Xu H, Krivtsov A, Nussenzweig A, Armstrong SA.
    Blood Adv; 2018 Oct 09; 2(19):2478-2490. PubMed ID: 30266823
    [Abstract] [Full Text] [Related]

  • 13. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
    Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, Evans WE, Reinhardt D, de Haas V, Hedtjärn M, Hansen BR, Koch T, Caron HN, Pieters R, Den Boer ML.
    Leukemia; 2013 Mar 09; 27(3):560-8. PubMed ID: 22940834
    [Abstract] [Full Text] [Related]

  • 14. AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.
    Ahmad K, Scholz B, Capelo R, Schweighöfer I, Kahnt AS, Marschalek R, Steinhilber D.
    Oncotarget; 2015 Sep 22; 6(28):25784-800. PubMed ID: 26329759
    [Abstract] [Full Text] [Related]

  • 15. Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement.
    Bueno C, Montes R, Catalina P, Rodríguez R, Menendez P.
    Leukemia; 2011 Mar 22; 25(3):400-10. PubMed ID: 21135858
    [Abstract] [Full Text] [Related]

  • 16. Pro-B-cell to pre-B-cell development in B-lineage acute lymphoblastic leukemia expressing the MLL/AF4 fusion protein.
    Bertrand FE, Vogtenhuber C, Shah N, LeBien TW.
    Blood; 2001 Dec 01; 98(12):3398-405. PubMed ID: 11719380
    [Abstract] [Full Text] [Related]

  • 17. MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene.
    Dou L, Li J, Zheng D, Li Y, Gao X, Xu C, Gao L, Wang L, Yu L.
    Mol Biol Rep; 2013 Dec 01; 40(12):6811-9. PubMed ID: 24057258
    [Abstract] [Full Text] [Related]

  • 18. MiR-27a downregulates 14-3-3θ, RUNX1, AF4, and MLL-AF4, crucial drivers of blast transformation in t(4;11) leukemia cells.
    Fioretti T, Zanobio M, Raia M, Errichiello S, Izzo B, Cattaneo F, Ammendola R, Cevenini A, Esposito G.
    Cell Biochem Funct; 2022 Oct 01; 40(7):706-717. PubMed ID: 35981137
    [Abstract] [Full Text] [Related]

  • 19. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.
    van der Linden MH, Willekes M, van Roon E, Seslija L, Schneider P, Pieters R, Stam RW.
    Cell Cycle; 2014 Oct 01; 13(5):834-44. PubMed ID: 24736461
    [Abstract] [Full Text] [Related]

  • 20. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
    Liu H, Westergard TD, Cashen A, Piwnica-Worms DR, Kunkle L, Vij R, Pham CG, DiPersio J, Cheng EH, Hsieh JJ.
    Cancer Cell; 2014 Apr 14; 25(4):530-42. PubMed ID: 24735925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.